Development of resistance-associated mutations after sotrovimab administration in high-risk individuals infected with the SARS-CoV-2 Omicron variant
E Birnie, JJ Biemond, B Appelman, GJ de Bree… - Jama, 2022 - jamanetwork.com
Methods| During the study period (January-February 2022), a single 500-mg dose of
sotrovimab was recommended for use in ambulatory and hospitalized high-risk patients with
SARS-CoV-2 infection. All patients treated at Amsterdam University Medical Centers in the
Netherlands were eligible. The study was approved by the medical ethical committee for the
Amsterdam University Medical Centers. Included patients provided written informed consent.
Nasopharyngeal specimens were prospectively collected on days 0, 7, and 28 (at the …
sotrovimab was recommended for use in ambulatory and hospitalized high-risk patients with
SARS-CoV-2 infection. All patients treated at Amsterdam University Medical Centers in the
Netherlands were eligible. The study was approved by the medical ethical committee for the
Amsterdam University Medical Centers. Included patients provided written informed consent.
Nasopharyngeal specimens were prospectively collected on days 0, 7, and 28 (at the …